Live
- Hyderabad court denies bail to 3 police officers in phone tapping case
- Apollo Hospitals' unit to raise Rs 2,475 crore from PE firm Advent International
- More than 70 per cent voter turnout in Assam till 5 PM
- Repeated and persistent doubts on EVMs can have contrarian impact of creating distrust: SC
- World Veterinary Day 2024: Celebrating Veterinarians as Guardians of Animal Welfare
- Addl DC Assured Measures to procure paddy
- Civil Engineer held in drug trade in Goa, contraband valued at Rs 8.5 lakh seized
- CM Vijayan loses cool when asked if elections would be assessment of his governance
- Punjab Congress chief challenges BJP to nominate state prez Jakhar to contest polls
- Mamata Banerjee continues to fire salvos at Calcutta HC against ruling in school jobs case
Zydus get DCGI nod to market rabies drug
Highlights
Zydus Cadila on Tuesday said it has received marketing authorisation for Twinrab, used for treating rabies, from the Drug Controller General of India .
New Delhi: Zydus Cadila on Tuesday said it has received marketing authorisation for Twinrab, used for treating rabies, from the Drug Controller General of India .
"The novel biologic which will be marketed under the brand name, Twinrab, is indicated in combination with rabies vaccine for rabies post-exposure prophylaxis," Zydus Cadila said in a statement.
Rabies, a viral disease which gets transmitted through the bite of a rabid animal, affects the central nervous system.
Zydus said in 2008, it had entered into an agreement with the World Health Organisation (WHO) to explore opportunities in the development of a cocktail of monoclonal antibodies for the treatment of rabies.
Next Story
ADVERTISEMENT
